Clinical Trials
35 trialsNCT07280377 2026-05-19
GOBLET
Oncolytics Biotech
Phase 1/2 Active not recruiting
NCT05514990 2026-05-13
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
University of Southern California
Phase 1/2 Active not recruiting
NCT07446322 2026-05-05
FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer
Oncolytics Biotech
Phase 2 Recruiting
NCT04445844 2025-04-04
INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
Rutgers, The State University of New Jersey
Phase 2 Active not recruiting
NCT04215146 2025-01-16
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
Oncolytics Biotech
Phase 2 Active not recruiting
NCT02101944 2024-05-17
Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Completed
NCT05519059 2023-11-22
Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer
Adlai Nortye Biopharma Co., Ltd.
Phase 1 Completed
NCT03605719 2023-10-06
Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma
Emory University
Phase 1 Completed
NCT01622543 2023-08-23
Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT02514382 2023-08-14
Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Southern California
Phase 1 Completed
NCT01619813 2023-08-04
Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT01656538 2023-08-04
A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT01708993 2023-08-04
Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy
Canadian Cancer Trials Group
Phase 2 Completed
NCT02444546 2023-04-24
Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors
Mayo Clinic
Phase 1 Completed
NCT03723915 2022-10-05
Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer
Northwestern University
Phase 2 Terminated
NCT04102618 2022-08-15
AWARE-1
Oncolytics Biotech
Phase EARLY_PHASE1 Terminated
NCT01199263 2020-09-16
Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03015922 2020-01-22
MUKeleven
University of Leeds
Phase 1 Unknown
NCT01274624 2018-12-19
Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Oncolytics Biotech
Phase 1 Completed
NCT02620423 2018-09-13
Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma
Oncolytics Biotech
Phase 1 Completed
NCT03282188 2018-05-04
REO13 Melanoma With of Without GM-CSF
University of Leeds
Phase 1/2 Withdrawn
NCT01280058 2018-03-09
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02723838 2017-03-07
Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder
Oncolytics Biotech
Phase 1 Withdrawn
NCT00602277 2016-08-08
Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy
National Cancer Institute (NCI)
Phase 1 Completed
NCT00998192 2016-03-31
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Oncolytics Biotech
Phase 2 Completed
NCT00861627 2015-12-02
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
Oncolytics Biotech
Phase 2 Completed
NCT01533194 2015-04-15
Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00984464 2015-04-10
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
Oncolytics Biotech
Phase 2 Completed
NCT00998322 2015-04-10
A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
Oncolytics Biotech
Phase 2 Completed
NCT01166542 2014-11-05
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
Oncolytics Biotech
Phase 3 Completed
NCT00753038 2014-11-04
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
Oncolytics Biotech
Phase 2 Completed
NCT00503295 2014-10-02
Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
Oncolytics Biotech
Phase 2 Completed
NCT00528684 2014-10-02
Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas
Oncolytics Biotech
Phase 1 Completed
NCT01240538 2014-05-13
Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00651157 2014-04-22
Viral Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed